SOURCE: Paragon Financial Limited

Paragon Financial Limited

May 18, 2012 08:20 ET

M&A Activity and a Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Success The Paragon Report Provides Stock Research on AEterna Zentaris and Celsion

NEW YORK, NY--(Marketwire - May 18, 2012) - The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry of mergers & acquisitions activity and a growing number of FDA approvals have been contributing factors to the industry's recent boom. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on AEterna Zentaris Inc. (NASDAQ: AEZS) and Celsion Corporation (NASDAQ: CLSN).

Access to full reports can be found at:

"In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010. We see an improving trend for FDA first cycle approvals and a rise in the rate of new drug approvals for rare diseases. We think these trends are helping to boost investor sentiment toward the agency, after years of criticism stemming from its inconsistency in making and communicating its decisions," Steven Silver, S&P Capital IQ Analyst, said in a recent note.

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. Revenues were $9.5 million for the quarter ended March 31, 2012, compared to $7.4 million for the same quarter in 2011.

Celsion Corporation is a clinical stage biopharmaceutical company singularly focused on developing its unique heat activated liposomal technology to create more efficacious versions of marketed cancer therapeutics that have the additional benefit of an improved safety profile. ThermoDox is currently being evaluated under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) in a global, multi-center, randomized, pivotal Phase III trial (the HEAT Study) in patients with non-resectable primary liver cancer.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: